Acorda Therapeutics (ACOR) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Acorda Provides Financial and Pipeline Update for First Quarter 2017
April 27, 2017 6:00 AM EDTCorporate restructuring implemented to focus on late-stage Parkinsons programs 2017 combined R&D and SG&A operating expense guidance revised to $330 - $350 million, a reduction of ~$50 million Projected year-end cash balance greater than $200 million AMPYRA® (dalfampridine) 1Q 2017 net revenue of $112.0 million; Company reiterates AMPYRA net sales guidance of $535 - $545 million
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc.... More
